Failure To Launch: Pravachol, Zocor And The Future Of 180-Day Exclusivity

Some of the most anticipated generic launches in recent years will be more limited than originally projected following court decisions creating 180-day exclusivity periods for generics of Bristol-Myers Squibb's Pravachol and Merck's Zocor